<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The biological activities of <z:chebi fb="0" ids="15551">prostaglandin E2</z:chebi> are mediated through their specific receptors, E <z:chebi fb="0" ids="26347">prostanoid</z:chebi> receptors (EPRs) </plain></SENT>
<SENT sid="1" pm="."><plain>This family comprises 4 subtypes (EP1R-4R), and has been associated with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> development and progression </plain></SENT>
<SENT sid="2" pm="."><plain>In <z:e sem="disease" ids="C0751571" disease_type="Neoplastic Process" abbrv="">urological cancers</z:e>, expression of EP2R and EP4R can be significant predictors of survival for <z:hpo ids='HP_0005584'>renal cell carcinoma</z:hpo> (<z:chebi fb="60" ids="47899">RCC</z:chebi>) </plain></SENT>
<SENT sid="3" pm="."><plain>On the other hand, EP1R, EP2R, and EP4R are known to be associated with <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> and malignant <z:hpo ids='HP_0000718'>aggressiveness</z:hpo> in <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, EP4R has been associated with <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> and prognosis in urothelial <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> of the upper urinary tract </plain></SENT>
<SENT sid="5" pm="."><plain>There is a general agreement that <z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drugs</z:chebi> (<z:chebi fb="1" ids="35475">NSAIDs</z:chebi>) can reduce the risk of several <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> including <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>However, <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> often cause gastrointestinal injury and <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>On the other hand, cyclooxygenase (COX)-2-selective inhibitors can reduce the progression of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> via the suppression of cell proliferation <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> without decreasing adverse reactions </plain></SENT>
<SENT sid="8" pm="."><plain>However, COX-2-selective inhibitors might increase the risk of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e>, including <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>More selective and detailed control of COX-2-mediated signals is thus needed to improve anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> effects and to decrease adverse reactions </plain></SENT>
<SENT sid="10" pm="."><plain>EPRs are expected to serve as new therapeutic targets in <z:e sem="disease" ids="C0751571" disease_type="Neoplastic Process" abbrv="">urological cancer</z:e>, because they are more selective in malignant phenotypes </plain></SENT>
<SENT sid="11" pm="."><plain>Finally, we speculate that some EPRs inhibitors may reduce adverse events and exert more intense effects on <z:e sem="disease" ids="C0751571" disease_type="Neoplastic Process" abbrv="">urological cancer</z:e> </plain></SENT>
</text></document>